By moving away from an “all or nothing” approach for covering innovative anti-obesity medications, the considerable potential savings incurred from the use of a lower-cost, alternative weight-maintenance program could allow substantially more people—particularly disadvantaged populations that are disproportionally affected by obesity24—access to GLP-1/IM treatment to produce optimal amounts of long-term weight loss and reduction in obesity-related sequelae.25 The gene discussed is GCG; the disease is Obesity.